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Abstract
Hepatocellular carcinoma (HCC) shows a rising incidence and mortality rates worldwide. 
HCC is divided into several distinct subtypes, both morphologically and histopathologically. 
Among these subtypes, infiltrative HCC may be the most challenging subtype to diagnose, 
given its characteristic myriad of tumor nodules blended with normal hepatocytes without 
a distinct mass-like lesion. Herein, we report an unusual case of an infiltrative HCC ini-
tially presenting with isolated malignant portal vein thrombosis and provide a brief review 
of the literature regarding the infiltrative HCC subtype. Additionally, we demonstrate how 
sonoelastography could aid in detecting the appropriate biopsy area in the infiltrative HCC 
subtype. To our knowledge, there have not been previously reported cases describing the use 















carcinosarcoma, carcinosarcoma with osteoclast-like giant 
cells and lymphocyte rich, in decreasing order of frequency(7). 
Among these, infiltrative type HCC may be the most difficult 
one to recognize both clinically and radiographically, because 
this HCC subtype is characterized by multiple minute tumor 
nodules that spread throughout the liver parenchyma, with-
out forming a mass-like lesion. Given this appearance of infil-
trative HCC, some authors have named this entity as diffuse 
HCC, cirrhotomimetic HCC, or cirrhosis-like HCC(6–14). 
Portal vein invasion is a known complicated feature of 
HCC, occurring by direct local venous extension or meta-
static spread. However, the initial presentation of HCC as 
an isolated portal vein thrombosis is incredibly rare, with 
very few cases reported in the English literature to date(15).
We, herein, present an unusual case of HCC initially pre-
senting as an isolated malignant portal vein thrombosis 
without any other findings suggesting HCC. Additionally, 
Introduction
Hepatocellular carcinoma (HCC) is predicted to be the sixth 
most common cancer and the fourth leading cause of cancer-
related death worldwide, with over 800,000 new cases and 
700,000 deaths annually(1). It is well known that HCC most 
commonly arises in the context of a cirrhotic background. 
The major causative factors for HCC include chronic infec-
tion with hepatitis B virus (HBV) or hepatitis C virus (HCV), 
aflatoxin exposure, excessive alcohol intake, smoking, obesity, 
type 2 diabetes, and certain inherited metabolic diseases(2–5). 
Various histopathologic and morphologic subtypes of HCC, 
some of which are not included in the WHO classification 
of the digestive system tumors, are described throughout the 
literature(6–8). El Jabbour et al.(7) described these HCC subtypes 
as steatohepatitic, clear cell, scirrhous, infiltrative, fibrola-
mellar carcinoma, combined hepatocellular-cholangiocarci-
noma, combined hepatocellular and neuroendocrine, granu-
locyte colony-stimulating factor producing, sarcomatoid, 
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we provide a brief review of the literature regarding the 
infiltrative type of HCC. To our knowledge, the use of sono-
elastography for the targeted liver biopsy has not been 
reported so far.
Case report
A 46-year-old woman was referred to our ultrasonography 
(US) department with the initial presumed clinical diag-
nosis of acute cholecystitis. She initially presented to the 
emergency department with epigastric and right upper 
quadrant pain. Physical examination revealed abdominal 
tenderness in the epigastrium and right upper quadrant 
with palpation and liver inferior limit at 4–5 cm below the 
costal margin. The blood test results on admission were as 
follows: hemoglobin = 12.3 g/dl, leucocytes = 5550/mm3, 
platelets = 303.000/mm3, AST=29 IU/l, ALT = 23 IU/l, total 
bilirubin = 1.21 mg/dl, HBS antigen (-) and anti-HCV (-). 
Gray-scale ultrasonography (US), Doppler US, and strain 
sonoelastography examinations were performed by an 
experienced radiologist with a Logiq S7 Expert machine 
(GE Healthcare, Milwaukee, WI) equipped with a C1-5-D 
convex probe. US examination revealed diffuse inho-
mogeneous left hepatic lobe without any localized for-
mation and significant dilatation of the left portal vein 
(26 mm) with thrombus extending into the right portal 
vein (Fig. 1, Fig. 2). Triphasic computed tomography (CT) 
of the liver was subsequently performed to collaborate 
with the US findings further. The entire left hepatic lobe 
showed enhancement during the arterial phase, followed 
by washout during the late venous phase (Fig. 3 A and B). 
Additionally, a tumor thrombus with a similar enhance-
ment pattern was demonstrated within the left and right 
portal veins (Fig. 3 A and B). In our case, neither US nor 
CT scans brought out any discrete mass-like lesion. Serum 
alpha-fetoprotein (AFP) level was within the normal range, 
as well. Given the lack of a discrete mass lesion, the sono-
elastography-guided biopsy was performed from the left 
liver lobe parenchyma (Fig. 4). The biopsy revealed infiltra-
tive hepatocellular carcinoma, which was later confirmed 
by immunohistochemistry.
Discussion
Infiltrative HCC accounts for approximately 10–20% of 
all HCC cases(16–20). It is characterized by multiple, wide-
spread minute tumor nodules throughout the liver, which 
appears as a spreading, ill-defined mass with indistinct 
margins. Although risk factors associated explicitly with 
infiltrative HCC are not well-established, there is emerging 
data suggesting an association with hepatitis B virus (HBV) 
infection(21,22). 
Serum alpha-fetoprotein (AFP) levels are reported to have 
poor diagnostic accuracy in infiltrative HCC, with variable 
serum AFP levels(23,24), even within the normal range, as 
with our case. However, other possible HCC serum bio-
markers, such as Lens culinaris agglutinin reactive AFP 
(AFP-L3) and Des-gamma-carboxyprothrombin (DCP), 
have recently been introduced, and AFP-L3 positivity is 
reported to be more commonly associated with infiltrative 
HCC subtype and to portend a poor prognosis(25–27).
Infiltrative HCC often poses a diagnostic challenge for 
radiologists to detect on cross-sectional imaging due to its 
infiltrating nature, especially in a heterogeneous cirrhotic 
background. Its histopathologic characteristics corre-
spond to permeative ill-defined appearance on cross-sec-
tional imaging. Ultrasonography (US), multiphasic con-
trast-enhanced computed tomography (CT) and magnetic 
resonance (MR) imaging are documented to be helpful for 
the diagnosis of infiltrative HCC. On US, the permeative 
ill-defined appearance of this entity is translated into het-
erogeneous echotexture. Although US plays a limited role 
in the diagnosis of infiltrative HCC(28), it can be used to 
detect appropriate area for targeted liver biopsy. In the 
setting of infiltrative HCC, sonoelastography could be 
Fig. 1.  Gray-scale US image shows the left portal vein expanded 
with occlusive tumor thrombus (white arrow)
Fig. 2.  Color Doppler US image reveals the presence of diagnostic 
arterial flow within the tumor thrombus
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Portal vein tumor thrombosis is a ubiquitous finding in 
infiltrative HCC(10,17–20,23,29–32, 34). It may even be the first 
sign of infiltrative HCC, as in our case(29). Tumor exten-
sion into the hepatic veins is not as common as the portal 
vein(30). On US, tumor thrombus may be seen as hypo/
hyperechoic intraluminal filling defects that expand the 
portal vein. The significant distension of the vessel, the 
arterialization of the thrombus, and the presence of pul-
satile flow in the thrombus are highly specific features of 
portal vein tumor thrombus(18–20,35–37). Contrast-enhanced 
US has recently been proposed to differentiate benign and 
malignant PV thrombi in patients with HCC(38,39). On con-
trast-enhanced CT and MR images, malignant thrombus 
exhibits a similar enhancement pattern to the originat-
ing tumor(18,37,40,41). Malignant thrombus shows restricted 
a more valuable tool than gray-scale US to guide biopsy 
to the area of concern. The affected area is coded differ-
ently in color, given its higher stiffness compared to the 
background non-infiltrated liver parenchyma. On multi-
phasic contrast-enhanced CT and MR imaging, infiltrative 
HCC may be inconspicuous because of its variable arterial 
enhancement pattern and following heterogeneous wash-
out appearance(11,17,19,29). Although washout appearance 
during the venous phase is reported to be less common in 
infiltrative HCC than in other HCC subtypes(17,19,30,31), it is 
still accepted as a valid sign to detect infiltrative HCC(32). 
More specifically, infiltrative HCC often seems hypoin-
tense to liver on T1-weighted sequences and hyperin-
tense to liver on T2-weighted with high b-value diffusion-
weighted sequences(11,17–20,23,29–33).
A B
Fig. 3.  Axial contrast-enhanced CT images show streaky and heterogeneous enhancement of the PV thrombus during the late arterial phase (A) 
with washout during the portal venous phase (B), which is diagnostic of tumor thrombus
Fig. 4.  On sonoelastographic image, normal parenchyma is coded in red-green color (star mark), whereas portal vein tumor thrombosis and 
the affected left lobe parenchyma are coded in blue-green (black arrow) and pure blue color (white arrow), respectively. Based on the 
color bar on the left side, red color reflects less stiff tissue, while blue color reflects more stiff tissue than the rest. Besides, green color 
reflects medium-stiff tissue
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diffusion and increased signal intensity on T2-weighted 
sequences as well(18,23,29,41).
A number of diseases including focal confluent fibro-
sis, geographic fatty infiltration, arterioportal shunting, 
microabscesses, cholangiocarcinoma, hepatic infarc-
tion, and diffuse metastatic disease (pseudocirrhosis) 
can mimic infiltrative HCC. Unlike HCC, focal conflu-
ent fibrosis generally seems hypovascular in the arte-
rial phase and exhibits delayed enhancement(18,20,31,42–44). 
Geographic fatty infiltration can be distinguished from 
infiltrative HCC by performing in- and out-of-phase, and 
fat-saturated MR sequences(18,20,45). Arterioportal shunt-
ing can be seen as a peripheral wedge-shaped area, only 
enhancing in the arterial phase without any abnormality 
on the delayed phase images(20). Hepatic microabscesses 
typically manifest as peripheral and septal enhancing 
lesions on contrast-enhanced CT and MR imaging, which 
is atypical for infiltrative HCC(46). The infiltrative nature 
of cholangiocarcinoma may cause diagnostic confusion. 
However, it should be kept in mind that cholangiocarci-
noma is less likely to be associated with tumor throm-
bosis and generally causes capsular retraction(11,47,48). 
Further, cholangiocarcinoma mostly shows peripheral 
centripetal enhancement pattern, which is uncharacter-
istic of infiltrative HCC(18). In a single case report, Shim 
et al. described a patient with hepatic infarction second-
ary to PV thrombophlebitis, which had been misdiag-
nosed as infiltrative hepatic malignancy with neoplas-
tic thrombus(49). Diffuse metastatic disease, especially 
related to treated metastatic breast cancer, can mimic 
cirrhosis and thus infiltrative HCC(50–52). In this regard, 
a clinical history of the primary cancer may lead to the 
correct diagnosis.
The prognosis of patients with infiltrative HCC is sub-
stantially worse when compared to those who have a 
focal/nodular subtype(21). Because most people with 
infiltrative HCC present at an advanced stage and 
have major vascular invasion at presentation(18,19,21,23), 
surgical resection and transplantation are usually 
considered unfeasible(18,19,53). The role of intra-arterial 
therapy in patients with infiltrative HCC is controver-
sial according to current conflicting research(23,54–56). 
Sorafenib, a multi-target tyrosine kinase inhibitor, 
was the first drug approved for the first-line treatment 
of advanced HCC and has shown favorable results 
to date(57–61). However, resistance or intolerance to 
sorafenib has given birth to new research concerning 
the second-line treatment options(62–64). Hsiao et al. doc-
umented that sorafenib with concurrent multiple-line 
therapies had significantly improved overall survival 
in patients with advanced HCC(65). Additionally, gene 
therapy, together with immunotherapy, is a promising 
treatment option on the horizon(66).
Conclusion
Infiltrative HCC often poses a diagnostic challenge for 
radiologists. Due to its diffuse and permeative nature, this 
entity is generally diagnosed at an advanced stage, which 
portends a poor prognosis. Isolated portal vein thrombo-
sis may be the first and the only sign of infiltrative HCC. 
Therefore, it is essential to follow up the patients with 
portal vein thrombosis in short intervals, even in the set-
ting of normal laboratory findings or the lack of a discrete 
mass. Knowledge of the critical tumor characteristics 
and imaging findings is crucial for radiologists to make 
a timely diagnosis and thus provide appropriate patient 
management.
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